ArticleNPJ breast cancer2016
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.
Article in NPJ breast cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).Breast cancer research : BCR · 2023Trial
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.Journal of the National Cancer Institute · 2019Trial
- Trial
- Venom-Derived Peptides in Breast Cancer: Pharmacological Mechanisms and Medicinal Chemistry-Guided Translational Development.Archiv der Pharmazie · 2026Review
- A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer.Breast cancer research : BCR · 2025Article
- Investigating the Immunogenic Cell Death-Dependent Subtypes and Prognostic Signature of Triple-Negative Breast Cancer.Phenomics (Cham, Switzerland) · 2024Article
- Dysfunction of ubiquitin protein ligaseNAR cancer · 2023Article
- Article
- PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer.NPJ breast cancer · 2022Article
- Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer.Breast cancer research and treatment · 2022Review
- Article
- Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling.Nature communications · 2021Article
- Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer.Nature reviews. Clinical oncology · 2019Review
- Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.Frontiers in oncology · 2019Review
- Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.Nature communications · 2018Article
- HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors.Breast cancer research : BCR · 2018Article
- Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.International journal of breast cancer · 2018Review
- Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example.Clinical & experimental metastasis · 2017Article
- Highlights from the Tenth European Breast Cancer Conference (EBCC10), Amsterdam, 9-11 March 2016.Ecancermedicalscience · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular landscape of high-risk breast cancer patients enrolled onto an adjuvant chemotherapy study to understand how disease subsets and tumor immune status impact survival. DNA and RNA were extracted from 861 breast cancer samples from patients enrolled onto the United States Oncology trial 01062. Samples were characterized using multiplex gene expression, copy number, and qPCR mutation assays. HR
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.